WHO assessing reports on risks related to AstraZeneca vaccine against Covid

A spokesperson for the WHO told Sputnik that its Global Advisory Committee on Vaccine Safety was carefully assessing the reports on risks related to the use of the AstraZeneca vaccine against Covid-19

AstraZeneca
Photo: Reuters
ANI Europe
2 min read Last Updated : Mar 12 2021 | 7:00 AM IST

A spokesperson for the World Health Organization (WHO) told Sputnik that its Global Advisory Committee on Vaccine Safety (GACVS) was carefully assessing the reports on risks related to the use of the AstraZeneca vaccine against COVID-19.

A number of European states have suspended vaccination with the AstraZeneca drug as a precaution after reports on severe side-effects, including blood clots, that were allegedly triggered by the vaccine, Sputnik reported.

The European Medicines Agency said there was currently no indication that the reported negative effects had been caused by the vaccination.

"The GACVS is carefully assessing the current reports on the AstraZeneca vaccine. As soon as WHO has gained a full understanding of these events, the findings and any changes to current recommendations will be immediately communicated to the public," the spokesperson said on late Thursday as quoted by Sputnik.

The WHO representative stressed that the global health body was aware of some EU countries' decisions to suspend the use of the AstraZeneca vaccine.

"The information available so far indicates that the number of thromboembolic events in vaccinated people is no higher than that seen in the general population. The Committee further noted that the vaccine can continue to be administered while the investigation of cases of thromboembolic events is ongoing," the spokesperson added.

The World Health Organization declared the COVID-19 outbreak a pandemic on March 11, 2020. To date, more than 118.34 million people have been infected with the coronavirus worldwide, with over 2.62 million fatalities, according to Johns Hopkins University.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Mar 12 2021 | 6:56 AM IST

Next Story